Abstract:Background Tumors often progress to a more aggressive phenotype to resist drugs. Multiple dysregulated pathways are behind this tumor behavior which is known as cancer chemoresistance. Thus, there is an emerging need to discover pivotal signaling pathways involved in the resistance to chemotherapeutic agents and cancer immunotherapy. Reports indicate the critical role of the toll-like receptor (TLR)/nuclear factor-κB (NF-κB)/Nod-like receptor pyrin domain-containing (NLRP) pathway in cancer initiation, progression, and development. Therefore, targeting TLR/NF-κB/NLRP signaling is a promising strategy to augment cancer chemotherapy and immunotherapy and to combat chemoresistance. Considering the potential of phytochemicals in the regulation of multiple dysregulated pathways during cancer initiation, promotion, and progression, such compounds could be suitable candidates against cancer chemoresistance. Objectives This is the first comprehensive and systematic review regarding the role of phytochemicals in the mitigation of chemoresistance by regulating the TLR/NF-κB/NLRP signaling pathway in chemotherapy and immunotherapy. Methods A comprehensive and systematic review was designed based on Web of Science, PubMed, Scopus, and Cochrane electronic databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed to include papers on TLR/NF-κB/NLRP and chemotherapy/immunotherapy/chemoresistance by phytochemicals. Results Phytochemicals are promising multi-targeting candidates against the TLR/NF-κB/NLRP signaling pathway and interconnected mediators. Employing phenolic compounds, alkaloids, terpenoids, and sulfur compounds could be a promising strategy for managing cancer chemoresistance through the modulation of the TLR/NF-κB/NLRP signaling pathway. Novel delivery systems of phytochemicals in cancer chemotherapy/immunotherapy are also highlighted. Conclusion Targeting TLR/NF-κB/NLRP signaling with bioactive phytocompounds reverses chemoresistance and improves the outcome for chemotherapy and immunotherapy in both preclinical and clinical stages.

Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals

Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies

The great escape: tumour cell plasticity in resistance to targeted therapy

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy

Emerging role of tumor cell plasticity in modifying therapeutic response

Phenotypic Plasticity and Cancer: A System Biology Perspective

Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior

Targeting Oncogene-Induced Cellular Plasticity for Tumor Therapy

Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

Phytocompounds targeting epigenetic modulations: an assessment in cancer

Deciphering cellular plasticity in pancreatic cancer for effective treatments

Chemotherapy induces cell plasticity; controlling plasticity increases therapeutic response

Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies

Phytochemical-mediated modulation of autophagy and endoplasmic reticulum stress as a cancer therapeutic approach

Cellular plasticity in the breast cancer ecosystem

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies

Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation

Targeting Dysregulated Lipid Metabolism in Cancer with Pharmacological Inhibitors